Johnson & Johnson (JNJ) has turned into one of the market’s steadier outperformers, with shares up roughly 55% over the past year as investors gain confidence in the company’s ability to grow beyond STELARA. Now, Morgan Stanley believes the healthcare giant may still have room to run. The firm …